PFE Stock Pfizer Inc.
US · NYSELast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Low valuation, cost reductions, and product replacement progress provide turnaround potential with income support.
Future value: $29.26 (-2.82%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Turnaround valuation and dividend support offset declining legacy products.
- ▸Above 50-day MA (+7.21%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (97.9% of range) — strength
- ▾Trading above its price target — limited upside
Is PFE a buy right now?
Trend: PFE is trading above the 50-day average (+6.11%), RSI 52 — neutral momentum, with a 3-month return of +21.73%.
Valuation & quality: Pfizer Inc. trades on a trailing P/E of 38.7, forward P/E 10.3, PEG 13.76, price-to-book 1.99; fundamentals show net margin 6.8%, return on equity 5.0%, revenue growth 2.6% year on year.
Analyst consensus: 26 analysts have a mean 12-month price target of $29.26 (-1.8% vs the last close; range $25.00 – $36.00), consensus rating “buy”.
Income: trailing dividend yield 5.73%.
Our screen: ACCUMULATE (score 1) — Low valuation, cost reductions, and product replacement progress provide turnaround potential with income support.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +1.60% | -4.90% | -1.90% | -8.00% | +3.90% | +13.80% | +0.20% | +5.30% |
Fundamentals
Analyst price target
Technical signals
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 75,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.